Bone density, an often-overlooked element of women’s health, plays a critical role in our overall well-being and quality of life as we age. Unlike cardiovascular fitness or muscle tone, which tend to receive more attention in discussions of women’s health, bone strength quietly underpins everything from our ability to move freely to our resistance against fractures and long-term disability. The gradual and often silent decline of bone density, particularly in women, makes early education and screening, such as bone density (DEXA) scans as early as age 50, a vital part of preventative health care.
Bone mineral density (BMD), refers to the amount of bone mineral (hydroxyapatite) in bone tissue. It is measured using a DEXA scan (Dual-Energy X-ray Absorptiometry), which evaluates the strength of bones and the likelihood of fractures. These scans yield two types of results: the T-score and the Z-score.
T-score compares your bone density to that of a healthy 30-year-old adult.
-
A T-score of -1.0 or above is normal.
-
A score between -1.0 and -2.5 indicates osteopenia, a condition where bone density is below normal and may lead to osteoporosis.
-
A score of -2.5 or lower signals osteoporosis, a disease characterized by fragile bones and an increased risk of fractures.
-
Z-score compares your bone density to the average of someone your age, sex, and weight.
-
A Z-score significantly below average (less than -2.0) may indicate that something other than aging is causing abnormal bone loss and should prompt further investigation.
For women, bone density is at its peak between the ages of 20 and 29. During this decade, the bones are the strongest and densest they will ever be. However, this window is fleeting.
Beginning around age
30, bone mass naturally starts to decline. The loss is slow and
steady at first, often going unnoticed. By the time we are in our
40s, the rate of bone loss begins to accelerate, especially in the
years leading up to menopause. Women may begin to show signs of
osteopenia even without symptoms. Around 50, we begin to enter
menopause and our estrogen levels drop dramatically. Because estrogen
is a key hormone in maintaining bone mass, this hormonal shift leads
to a rapid decrease in bone density, increasing the risk for
osteoporosis. In our 60s and beyond, without intervention, the risk
of osteoporosis rises sharply. By this time, many women may
experience fractures or learn of low bone mass only after an injury.
The
Role of Menopause and Hormonal Changes
Estrogen plays a
central role in bone remodeling, a process by which bones continually
rebuild themselves. During menopause, the sharp decline in estrogen
disrupts this balance, tipping the scale toward bone resorption
(breakdown) rather than bone formation. This is why women are at a
far greater risk of osteoporosis compared to men, especially after
menopause.
Conditions like early
menopause, surgical removal of ovaries, or amenorrhea (lack of
menstruation due to underweight or high physical stress) can bring on
early bone loss. Additionally, medications such as corticosteroids,
certain thyroid treatments, and even some cancer therapies can reduce
bone density over time.
Why
Get a Bone Scan by Age 50?
Many health
organizations recommend women begin routine DEXA scans at age 65 or
earlier if risk factors are present. However, by this age,
substantial bone loss may have already occurred. Detecting changes in
bone density by age 50 allows women to take early action, including:
Implementing Strength
Training: Resistance and weight-bearing exercises stimulate bone
formation. Women who lift weights, especially heavy weights such as
the compound barbell movements (squats, deadlifts, presses), tend to
maintain or even improve their bone density.
Supplementing Wisely:
Adequate intake of calcium and vitamin D is essential. Vitamin D
helps the body absorb calcium and maintain healthy levels in the
bloodstream. Women with vitamin D deficiency (below 30 ng/mL) are at
greater risk of bone loss and fractures.
Addressing Lifestyle
Risks: Smoking, excessive alcohol consumption, and very low
bodyweight all increase the risk of osteopenia and osteoporosis.
Identifying these factors early can allow for lifestyle interventions
that preserve bone mass.
Monitoring Medication
Impact: Some medications affect bone density. Early scans can help
track bone loss in women undergoing treatment for other conditions.
By age 50, most women
are entering perimenopause or are already in menopause. This period
is critical for assessing health risks, and adding a bone scan to
routine checkups can uncover issues before a fracture occurs. It
should be viewed as essential as mammograms or colonoscopies.
Real-World
Evidence: Case Studies in Strength
Below are real-world
case studies of four women between the ages of 50 and 70 and the
analysis of their bone scans during the time they implemented
strength training into their lifestyle.
Case Study No. 1:
M.S., a 75-year-old postmenopausal female.
M.S. has been training
at Fivex3 since December of 2019. Due to COVID, there was a 2.5 month
period from the middle of March to the end of May in 2020 when she
was unable to train due to the gym closure. M.S. resumed training in
June of 2020. She is a 75-year-old postmenopausal woman who underwent
a BMD scan in 2023 that revealed ongoing concerns regarding her
skeletal health. The scan indicated a diagnosis of osteoporosis in
the femoral neck and osteopenia in the lumbar spine, along with
moderate-to-high fracture risk over the next decade. Her previous
scan was in 2021, and she is currently taking Boniva, a prescription
medication used to treat and prevent osteoporosis in postmenopausal
women.
The World Health
Organization defines osteoporosis as a BMD T-score of -2.5 or lower.
M.S.’s scan results confirm this diagnosis in both hips:
- Left Femoral Neck:
T-score of -2.5 - Right Femoral Neck:
T-score of -2.8
These scores place her
firmly within the osteoporotic range and are clinically significant
because the femoral neck is a common site for debilitating hip
fractures in older adults. While her lumbar spine presents a T-score
of -1.7, this is categorized as osteopenia, a precursor to
osteoporosis that also carries a notable risk for fracture,
particularly in the setting of aging and hormonal changes.
The accompanying
Z-scores (Left Hip: -0.91; Right Hip: -0.85; Spine: 0.08) offer a
comparison to age-matched peers. These values suggest that while her
bone density is slightly below average in the hips, her lumbar spine
BMD is essentially average for someone her age.
One of the more
encouraging aspects of the 2023 report is the positive trend in bone
density compared to her 2021 scan (during which she was training
consistently 3x week):
-
Left Hip: +2.9%
increase in BMD -
Right Hip: +6.9%
increase -
Lumbar Spine:
+6.2% increase
These gains suggest
mild but meaningful improvements, possibly due to lifestyle changes,
residual effects of previous medications, or increased
calcium/vitamin D intake. However, these improvements, while
statistically notable, do not reverse the underlying diagnosis. M.S.
still qualifies as osteoporotic in both hips and remains at high
fracture risk. But while she may qualify as osteoporotic in her hips,
I would like to see a newer scan in 2025. If there was an increase in
both hips and her lumbar spine between 2021 and 2023, I imagine there
would be another increase in BMD between 2023 and 2025/2026.
Case Study No.2:
H.P., a 59-year-old postmenopausal female.
H.P. is a 59-year-old
female undergoing treatment for bone health and has had several BMD
scans over the years, providing a valuable longitudinal dataset for
understanding her skeletal health trajectory. She has been taking
prednisone – a corticosteroid – for about 15 years.
Corticosteroids are well known for their catabolic effects,
particularly in reducing bone mineral density. H.P. was diagnosed
with osteoporosis three years ago.
Her data spans from
2010 (age 43) to 2024 (age 58), and includes measurements taken
before and after notable clinical interventions or medication usage.
In 2010 H.P. started taking medication for bone density. H.P. joined
a gym in 2007 and has been very active during the years between 2007
and 2023. Prior to October 2023, her fitness routine included
spinning, body pump, and boot camp-style workouts 4–5 times per
week.
Her first scan was in
2010 and at this time, H.P.’s BMD at the AP spine was 0.925 g/cm³,
corresponding to a T-score of -1.1, which falls into the “osteopenia”
range. By 2012, there was a modest increase to 0.940 g/cm³
(T-score: -1.0), an improvement of 1.7%. This mild gain, though
small, indicated relative skeletal stability during this early
period. In 2010, H.P.’s left hip BMD was 0.920 g/cm³
(T-score: -0.2), considered within the normal range. By 2012, the
value increased slightly to 0.947 g/cm³
(T-score: 0.0), a 2.9% gain, indicating healthy bone remodeling and
density.
However, there was an
11-year interval between her scan in October of 2012 and her scan in
June of 2023 which saw a steep and concerning decline in spine BMD to
0.750 g/cm³,
a loss of approximately 18.9% from baseline and over 20% compared to
the 2012 level. The corresponding T-score dropped to -2.7, bordering
on the threshold of osteoporosis (defined as T-score -2.5). In
addition to her decline in the spine, from 2012 to 2023, her BMD at
the hip declined by approximately 13.9%, reaching 0.792 g/cm³
(T-score: -1.2), signaling a move into osteopenia territory. Although
the decline was less dramatic than at the spine, it still represented
a significant long-term reduction in bone strength and density.
What changed during
this time to cause such a dramatic decline? During this time period,
H.P. had stopped taking her bone density medication due to GI
complications and had also started hormone replacement therapy as she
was going through menopause. The decline in her BMD was almost
certainly due to her stopping her bone density medication and the
onset of menopause as well as her lack of weight-bearing exercise.
Despite H.P.’s active lifestyle, it is most certainly possible that
the nature of her exercise – while cardiovascularly beneficial –
did not sufficiently stimulate bone remodeling in a way that targeted
the areas most at risk for osteoporotic fractures (e.g., spine,
hips). This underscores a key difference between general fitness and
targeted resistance training in terms of bone health.
In October of 2023,
H.P. quit the gym she had been going to since 2007 and joined Fivex3 Training. She began a dedicated strength training program which
involved the compound lifts – squats, bench press, deadlift, and
overhead press. This meant no more boot camp classes, spinning, or
body pump classes. One year later, in October of 2024, she had her
fourth DEXA scan and a notable and encouraging shift occurred between
from June 2023 (four months before joining Fivex3) and October 2024,
with her BMD increasing in the AP Spine from 0.750 to 0.805 g/cm³
— a 7.2% gain. The T-score improved to -2.2, pulling it back into
the osteopenic range.
Most significantly,
this gain exceeds the Least Significant Change (LSC) threshold of
0.022 g/cm³,
which means the improvement is statistically significant and likely
reflects a true biological response rather than measurement
variability. This positive trend strongly indicates that H.P.’s
treatment – possibly pharmacologic (e.g., bisphosphonates, anabolic
agents) or lifestyle-based (e.g., her new strength training program)
– has been effective. In other words, the strength training program
was working!
Her BMD at the hip
remained relatively stable at 0.789 g/cm³
– a slight decrease of just 0.4%, which is well below the LSC of
0.027 g/cm³.
This minimal change suggests a plateau in bone loss at the hip,
possibly reflecting the stabilizing effects of treatment, although
not yet strong enough to induce a reversal as observed in the spine.
In conclusion, the AP
spine, which was the most critical area of concern due to the
dramatic loss between 2012 and 2023 was followed by a statistically
significant and clinically meaningful improvement in the last year.
This reversal implies effective recent intervention (like beginning a
strength training program). In the hip, the decline was less severe
compared to the spine, and while no significant improvement has
occurred yet, the recent stabilization is a positive sign that the
treatment may be beginning to halt further degradation.
As H.P. notes when we
discussed her most recent scan, “I am physically stronger and have
greater endurance. I also feel like I am psychologically stronger as
I am taking charge of my health and am combating aging and a health
condition that requires chronic steroid use. Getting yet another
diagnosis (osteoporosis) really weighed on me and after a short
period of being upset, I set out to put in the work required to at
least maintain the bone density that I have. So far it’s working!!”
Case Study No. 3:
E.R., a 70-year-old postmenopausal female.
E.R.’s bone health
trajectory over a six-year period from 2018 to 2024 offers an
informative and nuanced picture of skeletal aging and resilience. The
analysis focuses on two clinically significant regions: the
anteroposterior (AP) spine (L1–L4) and the left total hip. Notably,
E.R. has not used osteoporosis medications during this timeframe,
allowing an unfiltered view of natural or lifestyle-mediated changes
in bone mineral density. The data reveal divergent trends between the
spine and hip, warranting a targeted interpretation of her results.
E.R. started taking
CrossFit classes in 2018/2019 but then stopped attending those
classes in 2020 due to Covid. During this time, she also underwent
meniscus surgery on her left knee due to an injury and was doing PT
until October of 2020.
In November of 2020,
she began strength training at Fivex3 Training and has been training
there 3 days a week for the past 4.5 years. We started very slowly,
being very conservative with the knee. In July of 2023, she had a
second meniscus surgery on the right knee. Before her surgery, she
was still training but having more and more difficulty with the knee.
She followed up her surgery with physical therapy for three months,
from July to September, and returned to Fivex3 Training in October
2023.
The AP spine has
demonstrated a favorable trajectory in BMD, progressing from a
baseline of 0.739 g/cm³
in 2018 to 0.797 g/cm³
in 2024. This 7.8% increase surpasses the region’s Least
Significant Change (LSC) threshold of 0.022 g/cm³,
confirming the gain is statistically significant and not merely a
reflection of measurement variability. More importantly, the
associated T-score improved from -2.8 to -2.3, remaining within the
osteopenic range but moving toward normal bone density.
This positive shift in
spinal BMD is clinically meaningful. It reverses a prior period of
decline, with the lowest recorded spine BMD occurring in 2022. The
rebound since then not only reflects bone recovery but also suggests
potential stabilization. Since no pharmacologic treatments were used,
this improvement likely stems from lifestyle interventions, such as
weight-bearing exercise (i.e. squats, bench, overhead press and
deadlift) and nutritional intake (calcium and vitamin D).
The left total hip
tells a more concerning story. From a baseline BMD of 0.786 g/cm³
in 2018, there was a net loss of 8.7%, culminating in a BMD of 0.718
g/cm³
in 2024. This reduction was accompanied by a T-score decline from
-1.3 to -1.8 – remaining within the osteopenic range but
approaching the threshold for osteoporosis. While the decline is
clinically significant, recent data provide a glimmer of cautious
optimism: between 2022 and 2024, there was a modest BMD increase of
0.019 g/cm³
(+2.7%).
The bone loss in the
left hip is not too surprising as it was the left knee that she had
injured in 2019 and had meniscus surgery prior to beginning her
strength program at Fivex3 Training. Despite this, the slowed rate of
decline suggests a potential stabilization in hip BMD. As with the
spine, the absence of pharmacological intervention points to
non-medication-related benefits, although the hip appears to be more
resistant to recovery. This could reflect differences in mechanical
loading or regional sensitivity to systemic changes. (i.e. her knee
surgery.)
E.R.’s six-year bone
health experience reflects both vulnerability and resilience. Her
spine has demonstrated a meaningful and statistically significant
improvement in BMD, offering evidence of positive change and
effective skeletal maintenance without medication. Conversely, her
hip has undergone a moderate decline, with only recent signs of
possible stabilization.
Case Study No. 4:
L.H., a 60-year-old postmenopausal woman.
Between 2021 and 2025,
L.H. underwent three DEXA scans that tracked her progression and
partial recovery of bone mineral density (BMD) during a medically
complex period. Her skeletal health shifted from osteopenia to
osteoporosis and then back toward osteopenia, reflecting the combined
impact of trauma, systemic illness, pharmacologic therapy, and
lifestyle modifications, including structured resistance training.
L.H. had her first DEXA scan in February of 2021, prompted by family
history concerns. Her initial DEXA scan revealed osteopenia at
multiple skeletal sites.
-
Lumbar
Spine: BMD 0.874 | T-score: -1.6; Z-score: -0.4 Osteopenia -
Left
Hip (Total): BMD 0.852 | T-score: -0.7; Z-score: 0.0 Normal -
Left
Femoral Neck: BMD 0.671 | T-score: -1.6; Z-score: -0.5 Osteopenia -
A
1-inch height loss (from 5’6″ to 5’5″) was documented,
possibly due to early spinal compression or postural shifts. At this
stage, bone loss was mild and did not meet criteria for
osteoporosis. -
Two
years later, she had a follow up scan in March of 2023 and
unfortunately, it was not what she expected as it marked significant
deterioration. -
Lumbar
Spine: BMD 0.762 | T-score: -2.6; Z-score: -1.3 Osteoporosis -
Left
Hip (Total): BMD 0.791 | T-score: -1.2; Z-score: -0.4 Osteopenia -
Left
Femoral Neck: BMD 0.610 | T-score: -2.2; Z-score: -0.9 Osteoporosis
However, prior to this
2023 scan, in November 2022, L.H. suffered three pelvic fractures in
a high-speed bicycle accident. This traumatic event most likely led
to decreased mobility and increased systemic stress, both risk
factors for rapid bone loss.
To add more fuel to the
fire, one year later, in February of 2024, L.H. had a CT scan
followed by a PET scan in March, as well as a Bronchoscopy (a medical
procedure where a doctor uses a thin, flexible tube called a
bronchoscope to examine the airways and lungs). After this procedure,
she was diagnosed with lung cancer and had a lobectomy of the upper
left lung and a wedgectomy (wedge resection) of the lower left lung.
She began chemotherapy in June of 2024 and completed her last
treatment in August. L.H. began immunotherapy in September of 2024.
One year later, in June
of 2025, she had her third bone scan. This scan was much more
promising than her 2023 scan. Despite a lung cancer diagnosis and
intensive treatment, L.H’s 2025 DEXA scan showed modest BMD
improvement across all measured sites. Notably, the lumbar spine
T-score improved enough to move out of the osteoporotic range,
indicating successful skeletal stabilization. This is especially
remarkable given the bone-depleting effects of chemotherapy and
systemic illness.
- Lumbar Spine: BMD 0.805
| T-score: -2.2; Z-score: -07 Osteopenia (improved from osteoporosis)
– An increase of 5.7% - Left Hip (Total): BMD
0.824 | T-score: -1.0; Z-score 0.0 Osteopenia (getting close to being
normal again) – An increase of 4.1% - Left Femoral Neck: BMD
0.625 | T-score: -2.0; Z-score 0.7 Osteopenia – An increase of 2.5%
What could have made
the difference between her 2023 scan of osteoporosis and her 2025
scan that put her back in the osteopenia range?
1. She began a once a
year infusion of Reclast, a potent once-yearly bisphosphonate that
reduces bone turnover and fracture risk.
2. She began a
consistent, once-a-week strength training program in June of 2024 at
Fivex3 Training.
On May 28, 2024, L.H.
emailed Fivex3 Training. “Hello. I am 59 and have been an athlete
most of my life. Recently diagnosed with both osteoporosis and
cancer. I am looking for a strength program to maximize my muscles
and do my best to bulk up.”
On June 10, 2024, one
week after her first chemotherapy treatment, L.H. began a structured
weekly barbell strength training program, incorporating squats, bench
presses, overhead presses, and deadlifts. She continued this regimen
throughout chemotherapy (June – August) and immunotherapy (September
– July) and remains consistent with it today.
This type of
high-intensity, compound movement training is one of the most
effective non-pharmacologic strategies for stimulating osteogenesis,
particularly in postmenopausal women. Its timing – coinciding with
BMD improvement despite systemic stress – strongly suggests a
positive synergistic effect alongside Reclast in promoting skeletal
resilience.
L.H.’s case is a
compelling example of how multi-modal intervention – pharmacologic,
rehabilitative, and behavioral – can improve bone health even in
the context of trauma and systemic disease. Her BMD gains, while
modest, are clinically meaningful and encouraging. With continued
engagement in treatment and lifestyle management, L.H.’s skeletal
health can remain stable – or even improve – despite age-related
and oncologic challenges.
Case Study No. 5:
E.S., a 50-year-old menopausal female.
E.S. is a 50-year-old
woman whose bone health reflects the long-term benefits of an active
lifestyle and strength training. Her first and recent DEXA scan
reveals a skeletal profile that is not only well-preserved but also
unusually robust for her age. This case provides a unique opportunity
to explore the intersection of lifestyle, physiology, and diagnostic
interpretation in the context of bone health.
E.S. has maintained a
physically active lifestyle for nearly her entire life. From early
childhood until age 35, she participated in dance, first at a
competitive level and later recreationally. At age 35, she
transitioned into strength training, engaging in consistent,
progressive resistance exercise for the past 15 years. Her regimen
includes fundamental compound movements such as squats, deadlifts,
bench presses, and overhead presses – exercises known to exert high
mechanical loads on the skeleton, especially on weight-bearing bones
such as the spine and hips. This longstanding commitment to
physically demanding activity is a key contextual factor for
interpreting her DEXA results.
E.S.’s DEXA scan of
the lumbar spine (L1–L4) showed individual BMD values ranging from
1.341 to 1.440 g/cm³,
with an average of 1.366 g/cm³.
These values translate to T-scores between +3.0 and +3.6, and
Z-scores between +3.6 and +4.3. According to the World Health
Organization (WHO), a normal T-score lies between -1.0 and +1.0. Her
scores far exceed this range, indicating a bone density more than
three standard deviations above the young adult mean – an
extraordinarily rare outcome.
While high BMD is
typically advantageous and suggests superior skeletal strength, the
magnitude of E.S.’s scores is unusual. Z-scores greater than +2.0
are also considered elevated when compared to age-matched norms,
which may prompt further evaluation. Although these results raise
questions about potential underlying factors, they must be
interpreted in the broader context of her health and lifestyle.
In contrast to the
exceptionally high spinal scores, E.S.’s femoral neck and total hip
BMD results fall within the high-normal range. Her femoral neck BMD
measured 1.029 g/cm³
with a T-score of +1.6, while her total hip BMD was 1.158 g/cm³
with a T-score of +1.8. Z-scores for these regions were +2.4 and
+2.2, respectively. These values confirm that E.S.’s skeletal
robustness is not isolated to the spine and reflect consistent
adaptation across multiple anatomical sites due to mechanical loading
and muscular development.
To complement BMD, her
lumbar spine DEXA image was also analyzed using Trabecular Bone Score
(TBS), which evaluates bone microarchitecture. Her TBS was 1.552,
well above the threshold of 1.31 that indicates healthy trabecular
structure. This finding affirms the quality and organization of her
bone tissue, supporting the interpretation that her high BMD reflects
not just density but also structural integrity.
E.S.’s comprehensive
scan results suggest an extremely low risk of osteoporotic fracture.
Her elevated BMD, favorable TBS, and absence of any history of
fragility fractures all contribute to a skeletal profile that is
resilient and structurally sound. The FRAX tool, used to estimate
10-year fracture probability, was deemed unnecessary due to her high
T-scores, further underscoring her low risk.
E.S.’s case
exemplifies how a lifetime of physical activity – particularly
involving weight-bearing and resistance training – can yield
extraordinary benefits for skeletal health. Her results not only
highlight the potential of lifestyle interventions in preserving bone
strength but also serve as a reminder to approach outlier values with
careful, contextual interpretation. E.S. represents an optimal case
of midlife bone health. Her DEXA scan results reflect both a
high-density and high-quality skeletal structure, positioning her at
minimal risk for fracture and providing a powerful model for healthy
aging.
Conclusion:
Strong Bones, Stronger Women
Women no longer need to
accept declining bone density as just a “part of aging” or suffer
silently through the consequences. We are in an era where information
is accessible, preventative care is encouraged, and personal agency
is celebrated.
Talking about
menopause, osteopenia, and osteoporosis openly – as Gen X women are
doing now – allows us to rewrite the narrative for ourselves and
future generations. A DEXA scan at age 50 is not just a diagnostic
test. It’s a declaration that you matter, that your health is worth
tracking, and that you are not powerless in the face of aging.
Strong bones are not
built in a day, but the decision to start protecting them can be made
today.
Discuss in Forums
Credit : Source Post
